NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM)

Medicine & Life Sciences

1. Portugal 100%
2. Mental Health 42%
3. Therapeutics 41%
4. Systematic Reviews 36%
5. Neoplasms 33%
6. Global Health 33%
7. Health Surveys 31%
8. Population 30%
9. Biomarkers 27%
10. Genes 25%
11. Health 25%
12. Mortality 23%
13. Cohort Studies 23%
14. Mutation 23%
15. Proteins 21%
16. Heart Failure 20%
17. Guidelines 20%
18. Quality of Life 20%
19. Depression 20%
20. Pharmaceutical Preparations 19%
21. Rheumatic Diseases 19%
22. Meta-Analysis 19%
23. Mental Disorders 19%
24. Pandemics 19%
25. Carotid Body 18%
26. Child 18%
27. Intensive Care Units 18%
28. Dementia 18%
29. Infections 17%
30. Asthma 17%
31. Parkinson Disease 16%
32. Breast Neoplasms 16%
33. Rheumatoid Arthritis 16%
34. Delivery of Health Care 15%
35. Glucose 15%
36. Type 2 Diabetes Mellitus 15%
37. SARS Virus 15%
38. Cross-Sectional Studies 15%
39. Diet 14%
40. Thyroid Neoplasms 14%
41. Registries 14%
42. Prospective Studies 14%
43. Coronary Artery Disease 14%
44. Phenotype 14%
45. Liver 14%
46. Zebrafish 14%
47. Odds Ratio 14%
48. Kidney 14%
49. Coronavirus 13%
50. Gold 13%
51. Exercise 13%
52. Confidence Intervals 13%
53. Caregivers 13%
54. Insulin Resistance 13%
55. Food 13%
56. Rheumatology 13%
57. Lung 13%
58. Survival 12%
59. Blood Vessels 12%
60. Elderly 12%
61. Hypertension 12%
62. Inflammation 12%
63. Insulin 12%
64. In Vitro Techniques 12%
65. C-Reactive Protein 12%
66. Obstructive Sleep Apnea 12%
67. Ankylosing Spondylitis 12%
68. DNA 11%
69. Osteoarthritis 11%
70. Epidemiology 11%
71. Primary Health Care 11%
72. Critical Illness 11%
73. Safety 11%
74. Arteries 11%
75. Economics 11%
76. Income 11%
77. Obesity 11%
78. Psychiatry 11%
79. Observational Studies 11%
80. Fibromyalgia 11%
81. Comorbidity 11%
82. Bone and Bones 10%
83. Alzheimer Disease 10%
84. alpha-Synuclein 10%
85. Sleep 10%
86. Pregnancy 10%
87. Stroke 10%
88. Serum 10%
89. Clinical Trials 10%
90. Pneumonia 10%
91. Antibodies 10%
92. Hypoxia 10%
93. Randomized Controlled Trials 10%
94. Consensus 10%
95. Chronic Obstructive Pulmonary Disease 10%
96. Antiphospholipid Syndrome 10%
97. Single Nucleotide Polymorphism 10%
98. Technology 10%
99. Equipment and Supplies 10%
100. Costs and Cost Analysis 10%